188 related articles for article (PubMed ID: 33931137)
1. Immunological and functional aspects of MAGEA3 cancer/testis antigen.
Das B; Senapati S
Adv Protein Chem Struct Biol; 2021; 125():121-147. PubMed ID: 33931137
[TBL] [Abstract][Full Text] [Related]
2. Cancer/testis Antigen MAGEA3 Interacts with STAT1 and Remodels the Tumor Microenvironment.
Wang Y; Song X; Zheng Y; Liu Z; Li Y; Qian X; Pang X; Zhang Y; Yin Y
Int J Med Sci; 2018; 15(14):1702-1712. PubMed ID: 30588194
[TBL] [Abstract][Full Text] [Related]
3. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
5. [Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].
Imai N; Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2125-9. PubMed ID: 23259384
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma.
Craig AJ; Garcia-Lezana T; Ruiz de Galarreta M; Villacorta-Martin C; Kozlova EG; Martins-Filho SN; von Felden J; Ahsen ME; Bresnahan E; Hernandez-Meza G; Labgaa I; D'Avola D; Schwartz M; Llovet JM; Sia D; Thung S; Losic B; Lujambio A; Villanueva A
PLoS Genet; 2021 Jun; 17(6):e1009589. PubMed ID: 34166362
[TBL] [Abstract][Full Text] [Related]
7. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
Gjerstorff MF; Andersen MH; Ditzel HJ
Oncotarget; 2015 Jun; 6(18):15772-87. PubMed ID: 26158218
[TBL] [Abstract][Full Text] [Related]
9. Cancer/testis (CT) antigens: potential targets for immunotherapy.
Caballero OL; Chen YT
Cancer Sci; 2009 Nov; 100(11):2014-21. PubMed ID: 19719775
[TBL] [Abstract][Full Text] [Related]
10. The SSX family of cancer-testis antigens as target proteins for tumor therapy.
Smith HA; McNeel DG
Clin Dev Immunol; 2010; 2010():150591. PubMed ID: 20981248
[TBL] [Abstract][Full Text] [Related]
11. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
12. Cancer-testis antigens: An update on their roles in cancer immunotherapy.
Taherian-Esfahani Z; Dashti S
Hum Antibodies; 2019; 27(3):171-183. PubMed ID: 30909205
[TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
14. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MAGE A3 antigen in pancreatic cancer.
Cogdill AP; Frederick DT; Cooper ZA; Garber HR; Ferrone CR; Fiedler A; Rosenberg L; Thayer SP; Warshaw AL; Wargo JA
Surgery; 2012 Sep; 152(3 Suppl 1):S13-8. PubMed ID: 22770803
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Revels MAGEA3/6 as a Marker for Recurrence.
Zamunér FT; Karia BT; de Oliveira CZ; Santos CR; Carvalho AL; Vettore AL
Mol Cancer Ther; 2015 Mar; 14(3):828-34. PubMed ID: 25564441
[TBL] [Abstract][Full Text] [Related]
17. The potential immune-eliciting cancer testis antigens in colorectal cancer.
Chi Soh JE; Abu N; Jamal R
Immunotherapy; 2018 Sep; 10(12):1093-1104. PubMed ID: 30185136
[TBL] [Abstract][Full Text] [Related]
18. Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy.
Gordeeva O
Semin Cancer Biol; 2018 Dec; 53():75-89. PubMed ID: 30171980
[TBL] [Abstract][Full Text] [Related]
19. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.
Scanlan MJ; Gure AO; Jungbluth AA; Old LJ; Chen YT
Immunol Rev; 2002 Oct; 188():22-32. PubMed ID: 12445278
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.
Akers SN; Odunsi K; Karpf AR
Future Oncol; 2010 May; 6(5):717-32. PubMed ID: 20465387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
